BEVACZIUMAB PLUS FOSBRETABULIN IN RECURRENT OVARIAN CANCER: OVERALL SURVIVAL AND EXPLORATORY ANALYSES OF A RANDOMIZED PHASE II NRG ONCOLOGY/GYNECOLOGIC ONCOLOGY GROUP STUDY

OBJECTIVE: To explore the relationship between tumor size and response to combined anti-vascular targeted therapy using the anti-angiogenesis inhibitor, bevacizumab, and the tubulin-binding vascular disrupting agent, fosbretabulin. METHODS: An exploratory, post-hoc analysis of the randomized phase I...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Gynecol Oncol
Auteurs principaux: Tewari, Krishnansu S., Sill, Michael W., Coleman, Robert L., Aghajanian, Carol, Mannel, Robert, DiSilvestro, Paul A., Powell, Matthew, Randall, Leslie M., Farley, John, Rubin, Stephen C., Monk, Bradley J.
Format: Artigo
Langue:Inglês
Publié: 2020
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7789907/
https://ncbi.nlm.nih.gov/pubmed/32723679
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2020.07.015
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires